RNA Interference (RNAi) Drug Delivery market is segmented by Type and by Application. Players, stakeholders, and other participants in the global RNA Interference (RNAi) Drug Delivery market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
- Nanoparticle Drug Delivery Technology
- Pulmonary Drug Delivery Technology
- Nucleic Acid Drug Delivery Technology
- Aptamer Drug Delivery Technology
Segment by Application
- Infectious Diseases
- Cardiology
- Oncology
- Neurology
- Ophthalmology
- Metabolic Disorders
By Company
- Metabolic disorders
- Alnylam Pharmaceuticals Inc
- Merck & Co. Inc
- Access Pharmaceuticals Inc
- Dicerna Pharmaceuticals Inc
- Calondo Pharmaceuticals Inc
- Marina Biotech Inc
- RXi Pharmaceuticals Corp
- Quark Pharmaceuticals Inc
- Silence Therapeutics plc
- Tacere Therapeutics Inc
- PhaseRx Inc
- Sirnaomics Inc
- Traversa Therapeutics Inc
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- U.A.E
